The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2019 | PACIFIC trial updates: durvalumab after chemotherapy in NSCLC
Marina Garassino, MD, of National Cancer Institute of Milan, Milan, Italy, gives an update on the patient-reported outcomes from the Phase III PACIFIC study (NCT02125461), which investigated the efficacy of durvalumab in non-small cell lung cancer (NSCLC). Speaking at the European Lung Cancer Congress (ELCC) 2019, held in Geneva, Switzerland, Dr Garassino concludes that the administration of durvalumab did not significantly impact the quality of life in NSCLC patients.
